Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.17
+0.04003.54%
Post-market: 1.17-0.0002-0.02%18:42 EDT
Volume:416.95K
Turnover:478.20K
Market Cap:15.45M
PE:-1.04
High:1.18
Open:1.13
Low:1.11
Close:1.13
Loading ...

Hoth Therapeutics: Enrollment in Ht-001 Clinical Trial Is Proceeding as Planned

THOMSON REUTERS
·
09 Jan

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

PR Newswire
·
09 Jan

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Zacks
·
08 Jan

Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

GuruFocus.com
·
08 Jan

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
08 Jan

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
08 Jan

D. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ care

TIPRANKS
·
08 Jan

Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment

Dow Jones
·
07 Jan

Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint

MT Newswires Live
·
07 Jan

Hoth Therapeutics Shares up 83% on Positive Mid-Stage Trial Data for Skin Toxicity Treatment

THOMSON REUTERS
·
07 Jan

BUZZ-Hoth Therapeutics rises on positive mid-stage trial data for skin toxicity treatment

Reuters
·
07 Jan

Hoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001

TIPRANKS
·
07 Jan

Hoth Therapeutics Inc - Preserves Cancer Treatment Efficacy With Zero Dose Reductions

THOMSON REUTERS
·
07 Jan

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: Ht-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

THOMSON REUTERS
·
07 Jan

Hoth Therapeutics Inc - 100% of Patients Achieve Primary Efficacy Endpoint

THOMSON REUTERS
·
07 Jan

Hoth Therapeutics Inc: No Treatment-Related Adverse Effects Have Been Reported, Reaffirming Ht-001'S Excellent Tolerability

THOMSON REUTERS
·
07 Jan

Hoth Therapeutics Inc - No Treatment-Related Adverse Effects Observed

THOMSON REUTERS
·
07 Jan

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

PR Newswire
·
07 Jan